Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for OPKO Health, Inc. (OPK : NSDQ)
 
 • Company Description   
OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

Number of Employees: 5,767

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.09 Daily Weekly Monthly
20 Day Moving Average: 4,933,929 shares
Shares Outstanding: 681.53 (millions)
Market Capitalization: $2,105.91 (millions)
Beta: 1.88
52 Week High: $5.25
52 Week Low: $2.43
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.98% 14.85%
12 Week -4.33% 5.16%
Year To Date -35.76% -24.05%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4400 BISCAYNE BLVD.
-
MIAMI,FL 33137
USA
ph: 305-575-4100
fax: 305-575-6015
ybriggs@lhai.com http://www.opko.com
 
 • General Corporate Information   
Officers
Phillip Frost - Chief Executive Officer and Chairman of the Board
Jane H. Hsiao - Vice Chairman and Chief Technical Officer
Adam Logal - Senior Vice President; Chief Financial Officer;Chi
Steven D. Rubin - Executive Vice President-Administration and Direct
Richard Krasno - Director

Peer Information
OPKO Health, Inc. (ABMD)
OPKO Health, Inc. (DMDS)
OPKO Health, Inc. (CPWY.)
OPKO Health, Inc. (EQUR)
OPKO Health, Inc. (ECIA)
OPKO Health, Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 68375N103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 681.53
Most Recent Split Date: (:1)
Beta: 1.88
Market Capitalization: $2,105.91 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.01 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.30
Price/Cash Flow: 42.62
Price / Sales: 1.35
EPS Growth
vs. Year Ago Period: -260.00%
vs. Previous Quarter: 27.27%
Sales Growth
vs. Year Ago Period: -39.62%
vs. Previous Quarter: -17.97%
ROE
03/31/22 - -6.86
12/31/21 - -1.75
09/30/21 - 4.42
ROA
03/31/22 - -4.89
12/31/21 - -1.24
09/30/21 - 3.09
Current Ratio
03/31/22 - 2.44
12/31/21 - 2.49
09/30/21 - 1.97
Quick Ratio
03/31/22 - 2.12
12/31/21 - 2.23
09/30/21 - 1.57
Operating Margin
03/31/22 - -7.49
12/31/21 - -1.70
09/30/21 - 4.06
Net Margin
03/31/22 - -7.49
12/31/21 - -1.70
09/30/21 - 4.06
Pre-Tax Margin
03/31/22 - -7.85
12/31/21 - -0.79
09/30/21 - 5.23
Book Value
03/31/22 - 2.37
12/31/21 - 2.47
09/30/21 - 2.59
Inventory Turnover
03/31/22 - 9.91
12/31/21 - 9.68
09/30/21 - 9.05
Debt-to-Equity
03/31/22 - 0.13
12/31/21 - 0.11
09/30/21 - 0.11
Debt-to-Capital
03/31/22 - 11.53
12/31/21 - 10.03
09/30/21 - 9.51
 

Powered by Zacks Investment Research ©